Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287104 | PMC |
| http://dx.doi.org/10.5415/apallergy.0000000000000102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Idiopathic non-mast cell angioedema: Treatment insights from global experts.
Allergy Asthma Proc
January 2025
From the Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, California and.
Idiopathic non-mast cell angioedema (INMA) is a rare disease typified by recurrent attacks of cutaneous and subcutaneous swelling. Every attack carries the potential for severe morbidity and, in the case of laryngeal involvement, mortality. Whereas therapies approved for hereditary angioedema (HAE) have been used in the care of patients with INMA, little is known with regard to their efficacy for the treatment of this disease.
View Article and Find Full Text PDFThe international HAE guideline under real-life conditions: From possibilities to limits in daily life - current real-world data of 8 German angioedema centers.
Allergol Select
November 2024
Department of Oto-Rhino-Laryngology. Head and Neck Surgery, Ulm University Medical Center, Ulm.
Background And Objectives: Patients with rare diseases like hereditary angioedema (HAE) are usually referred to an angioedema center to ensure guideline-compliant and experience-based therapy. Even though there are established guidelines and several approved therapeutics, there are still open questions and situations in the daily care of HAE patients, where an exchange between centers is needed.
Materials And Methods: A survey was conducted among physicians from German angioedema centers regarding challenges and issues in everyday HAE treatment.
Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review.
Clin Rev Allergy Immunol
December 2024
Grenoble Alpes University, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, National Reference Center for Angioedema (CREAK), CHU Grenoble Alpes, TIMC, Grenoble, France.
Long-term prophylaxis (LTP) has been shown to reduce the frequency of hereditary angioedema (HAE) attacks; however, attacks occurring in patients receiving LTP have not been well characterized. The objective of this systematic review was to evaluate the proportion of type I/II HAE (HAE-C1INH) patients who experience attacks while receiving LTP, the characteristics of these attacks, and associated on-demand therapy use. A systematic search was conducted in PubMed to identify studies reporting LTP use with plasma-derived C1 inhibitor (pdC1INH), lanadelumab, berotralstat, androgens, or antifibrinolytics in patients with HAE-C1INH.
View Article and Find Full Text PDFInitial Experience of Long-Term Prophylaxis with Lanadelumab for Hereditary Angioedema in China: A Clinical Observation Study on Six Patients.
Int Arch Allergy Immunol
October 2024
Department of Allergy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Article Synopsis
- Hereditary angioedema (HAE) is a rare genetic disorder that causes recurrent swelling due to a deficiency in a specific inhibitor, and lanadelumab has been the primary long-term treatment option in China since 2020.
- A study involving 6 patients showed that lanadelumab significantly reduced the frequency of HAE attacks by up to 98.5%, improved quality of life, and decreased lost workdays by nearly 99% during the initial treatment phases.
- The findings suggest that lanadelumab is both effective and safe for managing HAE in Chinese patients, maintaining its efficacy even during the COVID-19 pandemic without any severe adverse effects.
The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center.
Front Immunol
May 2024
Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Article Synopsis
- Lanadelumab is a medicine used to help people with hereditary angioedema (HAE) and has been studied over 4 years for how well it works and if it's safe.
- Out of 34 patients treated with lanadelumab, most were still doing well after 4 years, with many reporting fewer attacks and feeling satisfied with their treatment.
- The study showed that lanadelumab is effective and safe in real life, and it suggests that patients may not need extra short-term treatments when using it.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!